Addressing the burden of chronic fibrotic diseases
Rila is advancing a lead program to treat kidney fibrosis
Rila Therapeutics, established with technology pioneered by Drs. John He and Kyung Lee at the Icahn School of Medicine at Mount Sinai, is a clinical-stage company dedicated to advancing innovative treatments for fibrosis. Our primary focus is on developing safe and efficacious anti-fibrotic therapies. Leading our efforts is a groundbreaking small molecule allosteric inhibitor designed to target HIPK2 in kidney fibrosis. This program has entered phase 1 clinical trials as of May 2024. The prevalence of renal fibrosis presents a significant, unmet medical need, as it underpins the progression of chronic kidney disease towards end-stage renal failure.
Rila Therapeutics is advancing first in class programs targeting signaling pathways playing a critical role in fibrosis.
ShangPharma Innovation identifies transformational healthcare discoveries at leading research labs and medical centers, then provides the right combination of resources needed to reach critical development milestones.
Dr. John Cijiang He is a Professor of Medicine and Pharmacological Sciences at Icahn School of Medicine at Mount Sinai. He holds the title of Irene and Dr. Arthur M. Fishberg endowed chair of Nephrology. He is the division chief of Nephrology at Mount Sinai Health System. He has more than 30 years of research experience, and his laboratory has been continuously funded by NIH for the last 20 years. His research interest has been in the fields of kidney cell biology and the mechanisms of chronic kidney disease including kidney fibrosis. His lab uses the systems biology approach to identify potential new biomarkers and drug targets for chronic kidney diseases. As one of these examples, his lab used systems biology approach to identify HIPK2 as a key driver for kidney fibrosis and this work leads to the discovery of HIPK2 inhibitors as anti-fibrosis drugs for chronic kidney disease. He has published more than 250 peer-reviewed papers in the fields.
Michael Hui
Founder and Chairman
Kyung Lee, PhD
Founder
Kyung Lee is an Associate Professor of Medicine at Icahn School of Medicine at Mount Sinai, Division of Nephrology. She has a long-standing focus on uncovering the molecular mechanisms governing disease initiation and progression in the early stages of chronic kidney disease. The scope of her research encompasses broad disease areas that include diabetic kidney disease, glomerulonephritis, HIV-associated kidney disease, and renal fibrosis. Dr. Lee has over 12 years of basic science research in nephrology and contributed to over 70 publications. She obtained her B.S. in Biochemistry from the State University of New York at Binghamton, Ph.D. in Molecular Cell and Developmental Biology at Icahn School of Medicine at Mount Sinai, and completed the post-doctoral fellowships at Columbia University Medical Center and Icahn School of Medicine at Mount Sinai.
Robert Drakas, PhD
CEO
Dr. Drakas is President of ShangPharma Innovation with more than 20 years experience leading therapeutic programs and cross function teams. He previously served as the Executive Director of Business Development at ChemPartner Inc., a leading research organization providing services for the biopharmaceutical industry. In addition, he was part of the founding team for ShangPharma Investment Group. Earlier in his career, Dr. Drakas served as senior analyst and senior research biochemist at Merck. He received a B.S. degree in biology from the University of Scranton, an M.S. in biochemistry from Drexel University and a Ph.D. in molecular pharmacology from Thomas Jefferson University. Dr. Drakas is board member of Blue Oak Therapeutics, Azkarra Therapeutics, ShangPharma Innovation, and board observer of Tilos Therapeutics, Mediar Therapeutics, and Evrys Bio.